Benjamin F. Edwards & Company, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 80 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80
Previous 182
56.04%
Holding current value
$0
Previous $8,000
62.5%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
7Shares Held
5.01MCall Options Held
3.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Segantii Capital Management LTD1.14MShares$05.99% of portfolio
-
Tekla Capital Management LLC176KShares$00.22% of portfolio
-
Credit Suisse Ag Zurich, V8112KShares$00.0% of portfolio
-
Kellner Capital, LLC New York, NY20.3KShares$01.55% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...